Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting May 5, 2025
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update March 12, 2025
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook January 14, 2025
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases November 4, 2024
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 12, 2024
